Nps Pharmaceuticals npsp.com


Public list: Pharma Startups (4732) Rare Diseases (230)

NPS Pharmaceuticals is developing specialty therapeutics for gastrointestinal and endocrine disorders. The company is currently advancing two late-stage programs: GATTEX (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and in preclinical development for the GI Mucositis and Necrotizing Enterocolitis indications and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 2 clinical development as a hormone therapy for hypo...Show all

NPS Pharmaceuticals is developing specialty therapeutics for gastrointestinal and endocrine disorders. The company is currently advancing two late-stage programs: GATTEX (teduglutide) is in Phase 3 clinical development for intestinal failure associat...Show all

Company (Acquired)

Phone: 908-450-5300

Fax: 908-450-5351

550 Hills Drive
3rd Floor
Bedminster, 07921
New Jersey, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Nps Pharmaceuticals $46.8M Jan 11, 2015
See all 18 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Nps Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 21 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Tragara Pharmaceuticals

San Diego, California, United States
Alive / ActiveTragara Pharmaceuticals is a pharmaceutical company focused on the clinical and commercial development of drugs for the treatment of various cancers. TG02 is an orally available, small molecule that targets - equipotently - the major signaling pathways involving ERK5, JAK2, and key cell cycle and transcriptional cyclin-dependent kinases (CDKs), with pharmacological and pharmaceutical properties. Preclinical models demonstrate that TG02 has the ability to deplete the short-lived survival proteins...Show allLogin to see details

Arriva Pharmaceuticals

Alameda, California, United States
Alive / ActiveArriva Pharmaceuticals, Inc. offers enzyme inhibitor replacement & therapyLogin to see details
See all 18 competitors